ADLM 2024 BOLD MOVE.

Laboratorians' Perspectives on Evaluation and Implementation of Alzheimer's CSF Assays

Tuesday, July 30
11:30 a.m. - 12:30 p.m.
Exhibit Hall Theater #1
Sponsored byRoche

OVERVIEW

Early detection of Alzheimer’s disease (AD) pathology can occur in vivo using fluid biomarkers and/or Positron emission tomography (PET) imaging. The US FDA approved/cleared cerebrospinal fluid (CSF) ratios can detect AD amyloid pathology early in the disease and correlate with amyloid PET. With the availability of amyloid removal therapies which slow down cognitive decline, it is expected that laboratories will be faced with increased requests for AD testing. In this workshop, a panel of laboratory experts will discuss particularities of evaluation and implementation of AD CSF biomarkers in clinical laboratories.

MODERATOR

Maria-Magdalena Patru, MD, PhD
Scientific Partner, CNS, Medical and Scientific Affairs, Roche Diagnostics

SPEAKERS

Nam Tran, PhD, MS, HCLD (ABB), CLS, MLS (ASCP)cm, FADLM
Senior Director, Clinical Chemistry, Toxicology and Point-of-Care Testing, Department of Pathology and Laboratory Medicine, University of California Davis Health

Heather Nelson, PhD, DABCC
Medical Director, Clinical Chemistry, ARUP Laboratories, University of Utah School of Medicine